News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,406 Results
Type
Article (41811)
Company Profile (473)
Press Release (663122)
Section
Business (208497)
Career Advice (2013)
Deals (35971)
Drug Delivery (97)
Drug Development (83402)
Employer Resources (169)
FDA (16357)
Job Trends (15055)
News (352302)
Policy (33000)
Tag
Academia (2619)
Alliances (50781)
Alzheimer's disease (1333)
Approvals (16310)
Artificial intelligence (172)
Bankruptcy (363)
Best Places to Work (11804)
Biotechnology (355)
Breast cancer (209)
Cancer (1559)
Cardiovascular disease (129)
Career advice (1678)
CAR-T (110)
Cell therapy (328)
Clinical research (66688)
Collaboration (593)
Compensation (311)
COVID-19 (2609)
C-suite (138)
Data (1490)
Diabetes (190)
Diagnostics (6253)
Earnings (86248)
Employer resources (147)
Events (113838)
Executive appointments (483)
FDA (17140)
Funding (533)
Gene therapy (234)
GLP-1 (654)
Government (4423)
Healthcare (19067)
Infectious disease (2706)
Inflammatory bowel disease (121)
Interviews (309)
IPO (16667)
Job creations (3696)
Job search strategy (1430)
Layoffs (451)
Legal (7945)
Lung cancer (227)
Manufacturing (222)
Medical device (13379)
Medtech (13384)
Mergers & acquisitions (19551)
Metabolic disorders (517)
Neuroscience (1717)
NextGen: Class of 2025 (6747)
Non-profit (4541)
Northern California (1883)
Obesity (295)
Opinion (204)
Patents (134)
People (57993)
Phase I (20936)
Phase II (29431)
Phase III (21759)
Pipeline (622)
Postmarket research (2599)
Preclinical (8946)
Radiopharmaceuticals (255)
Rare diseases (302)
Real estate (6001)
Regulatory (22231)
Research institute (2407)
Resumes & cover letters (351)
Southern California (1638)
Startups (3751)
United States (17020)
Vaccines (595)
Weight loss (211)
Date
Today (28)
Last 7 days (472)
Last 30 days (1893)
Last 365 days (35907)
2025 (1640)
2024 (36337)
2023 (41016)
2022 (52277)
2021 (56764)
2020 (54923)
2019 (47419)
2018 (35698)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (211)
Asia (38791)
Australia (6448)
California (4329)
Canada (1558)
China (367)
Colorado (193)
Connecticut (214)
Europe (84566)
Florida (600)
Georgia (146)
Illinois (428)
Indiana (242)
Maryland (698)
Massachusetts (3405)
Michigan (184)
Minnesota (320)
New Jersey (1203)
New York (1215)
North Carolina (840)
Northern California (1883)
Ohio (154)
Pennsylvania (1006)
South America (1107)
Southern California (1638)
Texas (626)
Utah (121)
Washington State (442)
705,406 Results for "denali therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ALS
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and Amylyx have seen similarly disappointing results.
January 7, 2025
·
2 min read
·
Tristan Manalac
ALS
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.
January 10, 2025
·
5 min read
·
Heather McKenzie
Press Releases
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 14, 2025
·
10 min read
Press Releases
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
January 9, 2025
·
6 min read
Business
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024, and provided business highlights.
May 7, 2024
·
13 min read
Neuroscience
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of brain-penetrant small molecules to address inflammation, metabolic dysfunction and restoring lysosomal function.
January 8, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
January 7, 2025
·
7 min read
Press Releases
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 7, 2024
·
15 min read
Biotech Bay
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
Denali Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.
June 3, 2024
·
9 min read
Deals
Denali Therapeutics Announces $500 million Private Placement Equity Financing
Denali Therapeutics Inc. today announced that the company has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share.
February 27, 2024
·
6 min read
1 of 70,541
Next
